

Kathleen Petrillo Quoted in *"The Pink Sheet"*

In the April 11, 2008 issue of *"The Pink Sheet,"* attorney Kathleen Petrillo comments on a recent court decision granting Teva Pharmaceuticals 180 days of market exclusivity for a generic version of the schizophrenia drug *Risperdal* (risperidone).

Teva was the first firm to file an Abbreviated New Drug Application (ANDA) with the FDA while the patent, owned by Johnson & Johnson, was still listed. Therefore, Ms. Petrillo notes, "I think Teva had a good case...The timing seems right for what Teva did. They were first in line." She adds that as more drugs lose patent protection, conflicts over generics are "likely to be a very active area of the law."

"The Pink Sheet" is a leading weekly publication covering the prescription pharmaceutical and biotechnology industries.

Ms. Petrillo's practice focuses on chemical and life sciences.